-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer is the most common malignant tumor in women worldwide and the second leading cause of cancer-related deaths
Breast cancer is the most common malignant tumor in women worldwide and the second leading cause of cancer-related deaths
The study included patients with HER2-negative metastatic breast cancer (MBC) who had previously received anthracyclines and taxanes and progressed after at least first-line treatment
The study included patients with HER2-negative metastatic breast cancer (MBC) who had previously received anthracyclines and taxanes and progressed after at least first-line treatment
31 eligible patients were included in the safety and efficacy assessment
Efficacy evaluation
The median progression-free survival was 6.
The median progression-free survival was 6.
PFS
16 patients (51.
16 patients (51.
The study found that the median PFS of patients with hypertension was significantly longer than that of patients without hypertension [7.
The most common grade 3/4 treatment-related AEs were hypertension (12/31,38.
In summary, studies have shown that apatinib combined with etoposide capsules is effective and tolerable for patients with metastatic HER2-negative breast cancer
Original source:
Hu N, Zhu A, Si Y, et al(2021)A PhaseII, Single-Arm Study of Apatinib and Oral Etoposide in Heavily PreTreated Metastatic Breast Cancer.
Front.
Oncol.
10:565384.
doi: 10.
3389/fonc.
2020.
565384
Front.
Oncol.
10:565384.
doi: 10.
3389/fonc.
2020.
565384
here message
